drugset
drugset / Trial / NCT05918978

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05918978 ↗

Phase 2 Terminated 33 enrolled argenx IQVIA Pty Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.

Timeline

Start
2023-06-20
Primary completion
2024-08-15
Completion
2024-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Efgartigimod Alfa Protein / enzyme biologic 10 mg/kg Intravenous

Indications

postural orthostatic tachycardia syndrome